• Corpus ID: 13485517

Rufinamide: CGP 33101, E 2080, RUF 331, Xilep.

  title={Rufinamide: CGP 33101, E 2080, RUF 331, Xilep.},
  journal={Drugs in R\&D},
  volume={6 4},
  • Published 2005
  • Medicine
  • Drugs in R&D
Rufinamide [E 2080, CGP 33101, RUF 331, Inovelon, Xilep] is the lead compound in a series of five-substituted phenylalkyl-3- carbamoyl-4H-1,2,4-triazoles with anticonvulsant activity that was discovered by Novartis AG. Although the precise mechanism of action for rufinamide is unknown, it is known that it limits the firing of sodium-dependent action potentials in neurons, hinting at a membrane-stabilising effect. Rufinamide is under regulatory review in Europe for epilepsy, and phase III trials… 
1 Citations

Safety and retention rate of rufinamide in 300 patients: A single pediatric epilepsy center experience

This work evaluated the use of rufinamide in a single pediatric center with a large cohort and long‐term follow‐up period and found it to be safe and effective in children with refractory epilepsy.